Research & Development
Pathology & AI
Pan-cancer study reveals epigenomic drivers for cancer development, progression
A team of researchers have identified epigenomic drivers associated with cancer development and progression, constructing a pan-cancer epigenetic and transcriptomic atlas from the data.
November 3, 2023
Exact Sciences, Watchmaker Genomics partner to improve DNA methylation technology
Exact Sciences has partnered with Watchmaker Genomics to develop and commercialize technology for analyzing DNA methylation.
September 6, 2023
Epigenetic study links DNA methylation to diseases including breast cancer and diabetes
Through the analysis, the researchers identified 69 associations between CpGs and the prevalence of breast cancer, chronic kidney disease, ischemic heart disease, and type 2 diabetes. The majority of the associations had not previously been described.
July 12, 2023
Promis Diagnostics nabs FDA breakthrough device designation for bladder cancer test
The EarlyTect BCD test qualitatively detects an epigenetic biomarker, PENK methylation, associated with bladder cancer in the urine DNA of patients with hematuria.
April 28, 2023
Cardio Diagnostics launches AI-based blood test for the early detection of coronary heart disease
PrecisionCHD is an integrated epigenetic-genetic blood test that uses machine learning for the early detection of coronary heart disease.
February 28, 2023
Analysis of genome-wide methylomic variations reveal epigenetic changes in Alzheimer’s brains
Multiple papers have already described DNA methylation differences associated with Alzheimer’s and other forms of dementia in several regions of the brain.
February 22, 2023
Volition collaborates with Heska on veterinary early cancer detection test launch
Volition announced that it has partnered with Heska to launch an enzyme-linked immunoassay-based blood screening test for cancer detection in older or “at risk” dogs.
November 3, 2022
Epigenetics firm Inherent Bio closes Series A round
Inherent said that its epigenetics platform detects dysregulation across multiple genes and related pathways.
September 6, 2022
Harbinger Health, SCRI to partner on clinical study
The study, called Cancer ORigin Epigenetics- Harbinger Health (CORE-HH), will enroll participants at up to 40 U.S. facilities; enrollment has begun at sites affiliated with HCA Healthcare, which is SCRI's parent company.
June 28, 2022
VolitionRx highlights COVID-19 triage test clinical trial results
The studies, which were conducted at the University Hospital Liege in Belgium and the German Heart Center in Munich, aimed to confirm whether circulating nucleosomes could serve as a potential prognostic marker for COVID-19 disease severity. The researchers found that the company's Nu.Q epigenetics technology correlated with more severe COVID-19 cases, implying strong prognostic potential, according to VolitionRx.
July 14, 2020
NYU Langone launches genetic profiling of brain tumors
The services are based on epigenetic research on central nervous system tumors published by NYU Langone's pathologists with the German Cancer Research Center in Heidelberg (Capper et al, Nature, March 22, 2018, Vol. 555:7697, pp. 469-474). The researchers used DNA methylation to improve the accuracy of diagnosis for brain tumors, and the classifier is available online at no cost.
October 27, 2019
Page 1 of 1